Abstract 1888P
Background
The increasing presence of cancer patients in palliative care within emergency departments (ED) worldwide calls for improved care quality. These patients often undergo unnecessary invasive procedures due to challenges in promptly assessing their treatment needs. We developed PalliScore, a rapid assessment tool aimed at helping medical professionals quickly identify palliative care patients in the ED who are less likely to benefit from invasive procedures or ICU admission.
Methods
We retrospectively analyzed data from cancer patients in palliative care admitted to the ED of our hospital in Southeast Brazil, calculating their PalliScore upon admission. This four-step tool incorporates diagnosis of an incurable and life-threatening disease, special care situations (e.g., family or medical team disagreements, uncontrolled symptoms), the “surprise question” (Would you be surprised if this patient died within the next 12 months?), and performance status (ECOG or PPS). Each criterion is scored to reflect the PalliScore, with a threshold of ≥5 suggesting a need to consider limiting invasive interventions after thorough discussion with the patient and healthcare providers.
Results
From March 2021 to July 2023, we assessed 521 patients; 70 (13.68%) received limited intervention care while 449 received intensive care. The average PalliScore was 6.50 for the limited care group and 2.77 for the intensive care group. Statistical analysis using an unpaired t-test showed a significant difference in PalliScore between the groups (odds ratio 3.73, p < 0.0001). Notably, 16.7% of patients with a PalliScore ≥ 5 still received intensive care treatments, whereas 10% of patients with a PalliScore < 5 received limited intervention care.
Conclusions
PalliScore effectively aids ED physicians in making informed decisions regarding invasive procedures and ICU admissions, thereby potentially improving the quality of care for cancer patients in palliative settings. This tool highlights the complex nature of decision-making in palliative care, emphasizing the need for sensitive and individualized patient assessments.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1873P - Thalidomide for the treatment of chemotherapy-induced night sweats in patients with pancreatic cancer
Presenter: Nan Lu
Session: Poster session 12
1874P - Time to vomiting after chemotherapy in association with number of emetic risk factors among breast cancer patients receiving highly emetogenic chemotherapy
Presenter: Winnie Yeo
Session: Poster session 12
1875P - Real-world evidence of ribociclib induced liver toxicity in patients with breast cancer: A multi-center experience
Presenter: Onur Bas
Session: Poster session 12
1877P - Adverse effects (AEs) of trastuzumab deruxtecan (T-DXd) in solid tumours: A meta-analysis
Presenter: Neha Pathak
Session: Poster session 12
1878P - Efficacy of surgical gloves (SG) as compression therapy to prevent oxaliplatin-induced peripheral neuropathy (PN): The ELEGANT trial
Presenter: Aurélia JOUREAU-CHABERT
Session: Poster session 12
1879P - Effectiveness of intravenous fosnetupitant & palonosetron for cinv prophylaxis in patients receiving highly emetogenic chemotherapy regimens: Subgroup analysis from a phase IV Indian study
Presenter: Arun Kumar Verma
Session: Poster session 12
1880P - Antiemetic prophylaxis during chemoradiation: Sub-study of the GAND-emesis trial identifying dosimetric predictors for vomiting
Presenter: Anika Johannsdottir
Session: Poster session 12
1881P - Enhancing chemotherapy-induced nausea and vomiting management: Insights into guideline adherence and patient outcomes
Presenter: Suresh Attili
Session: Poster session 12
1882P - Awareness of chemotherapy induced nausea and vomiting and adherence to guidelines: A multinational and multicenter survey
Presenter: Ricardo Caponero
Session: Poster session 12
1883P - Impact of geriatrician-implemented Interventions on chemotherapy (CT) delivery in vulnerable elderly patients with early or advanced solid tumors: The GIVE trial
Presenter: Emanuela Risi
Session: Poster session 12